Sort
10,766 grants matching “checkpoint inhibitor”
Core C Mouse Model Core
$166,160Alain Charest · Massachusetts General Hospital · P01 · FY2017 · CA
Nanoparticles for In Vivo Labeling of T Cells During Cancer Immunotherapy
$166,107Carlos M Rinaldi-Ramos · University Of Florida · R21 · FY2023 · CA
Targeting CDK4/6 as an interception strategy for intraductal papillary mucinous neoplasia
$166,037Jonathan Robert Weitz · University Of California, San Diego · K01 · FY2025 · CA
MOLECULAR PHARM. AND BIOCHEM. OF NOVEL DUAL SPECIIFICITY PHOSPHATASE INHIBITORS
$165,602University Of Pittsburgh At Pittsburgh · P01 · FY2005 · CA
Preventing Myeloma Relapse after Autologous Stem Cell Transplantation with Decoy Resistant IL-18
$165,584Geoffrey Roger Hill · Fred Hutchinson Cancer Research Center · U01 · FY2021 · CA
Identifying Therapeutic Vulnerabilities of c-MYC-driven Small Cell Lung Cancer
$165,300Trudy Gale Oliver · University Of Utah · R21 · FY2018 · CA
Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality Immunotherapies
$165,219Zachary Scott Morris · University Of Wisconsin-Madison · U01 · FY2022 · CA
Melanoma-mediated Dendritic Cell Tolerization and Immune Evasion
$165,132Brent Allen Hanks · Duke University · K08 · FY2017 · CA
Melanoma-mediated Dendritic Cell Tolerization and Immune Evasion
$165,132Brent Allen Hanks · Duke University · K08 · FY2019 · CA
Wwox and Fhit loss and the DNA damage response in breast cancer subtypes
$164,803Kay Huebner · Ohio State University · R01 · FY2010 · CA
Analysis of lung cancer stem cell radioresistance
$164,756Vera Levina · University Of Pittsburgh At Pittsburgh · R21 · FY2012 · CA
Project 1 Genetic and Immunologic Mechanisms Underlying Combination Sacituzumab plus Radiation Therapy for Bladder Cancer
$164,648Timothy An-Thy Chan · Cleveland Clinic Lerner Com-Cwru · U54 · FY2023 · CA
POTENTIATION OF TAXANE ACTIVITY BY MEK/MAPK INHIBITORS
$164,601Virginia Commonwealth University · R01 · FY2002 · CA
Targeting tissue factor as a novel oncotarget for immunotherapy of triple negative breast cancer
$164,560Zhiwei Hu · Ohio State University · R21 · FY2019 · CA
Preclinical Development of Therapeutics in Murine Models of Lung Cancer
$164,392Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Molecular Analysis and Precision Medicine in Renal Cell Carcinoma
$164,213Michael Hiroshi Johnson · Johns Hopkins University · K01 · FY2019 · ES
Molecular Analysis and Precision Medicine in Renal Cell Carcinoma
$164,213Michael Hiroshi Johnson · Johns Hopkins University · K01 · FY2017 · ES
Breaking immune tolerance to Survivin in Multiple Myeloma
$164,160Frederick Locke · H. Lee Moffitt Cancer Ctr & Res Inst · K23 · FY2018 · CA
Breaking immune tolerance to Survivin in Multiple Myeloma
$164,160Frederick Locke · H. Lee Moffitt Cancer Ctr & Res Inst · K23 · FY2017 · CA
Breaking immune tolerance to Survivin in Multiple Myeloma
$164,160Frederick Locke · H. Lee Moffitt Cancer Ctr & Res Inst · K23 · FY2019 · CA
An Engineered CRISPR System for Boosting Tumor Immunogenicity.
$164,000Weixin Tang · University Of Chicago · R21 · FY2023 · EB
Combination of tumor targeted therapy with stroma modulating agent for PDAC
$164,000Ketankumar D. Patel · St. John'S University · R16 · FY2023 · GM
Combination of tumor targeted therapy with stroma modulating agent for PDAC
$164,000Ketankumar D. Patel · St. John'S University · R16 · FY2024 · GM
Combination of tumor targeted therapy with stroma modulating agent for PDAC
$164,000Ketankumar D. Patel · St. John'S University · R16 · FY2025 · GM
Ciprofloxacin enhances DNA repair capacity after radiation combined injury
$163,987Juliann Gong Kiang · Henry M. Jackson Fdn For The Adv Mil/Med · R21 · FY2009 · AI